🔮 OOTWOracle · All predictions · Odds sheet · Track record · How it works · Benchmark
Answers: Will psilocybin be FDA-approved? · Will MDMA be approved? · When will psychedelics be legal?

The ibogaine-ketamine case report prompts no validated mechanistic study; any follow-up remains observational, not controlled, within 12 weeks.

Predicted 2026-08-04 · Resolves 2026-10-27 · research · Global
68%
ORACLE CONFIDENCE
⏳ Pending
Every outcome is scored publicly in the ledger.

Scientists don't yet understand the biology of why ibogaine might help someone stop using ketamine — the one published case offers a story, not an explanation. Properly designed studies that could actually test a mechanism (like a controlled experiment with a comparison group) take months or years to fund, design, and launch. By late October 2026, any follow-up work will almost certainly still be observational — meaning researchers watching and recording what happens naturally, not running a controlled experiment.

Resolution rule: YES if, by 2026-10-27, no controlled (randomized or mechanistic in-vivo/interventional) study on ibogaine-ketamine interaction is published or registered; only observational/case-report follow-ups appear. Check PubMed (search: ibogaine ketamine) and clinicaltrials.gov for interventional registrations dated after 2026-08-04. Resolves NO if a controlled/interventional study is published or registered.

Mechanism requires funded controlled work that isn't in place. The field will over-interpret an anecdote before the biology is understood.

5 new falsifiable predictions, every day at 12:05 PM ET.
Get tomorrow's Oracle →
Marketing byAN
Sacred 5-MeO-DMT Ceremonies · Miami
The Oldest Prayer, Remembered

Join our community — a free weekly Zoom circle with a master facilitator. Come sit with us first; the rest reveals itself.

Join the Free Weekly Circle →